Recombinant bispecific antibodies for cancer therapy

被引：104

作者：

Kontermann, RE ^{[1
]}

机构：

[1] Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany

来源：

ACTA PHARMACOLOGICA SINICA | 2005年 / 26卷 / 01期

关键词：

antibody engineering; bispecific antibody; diabodies; single-chain diabodies; tandem scFv; targeting; effector cells; cancer therapy;

D O I：

10.1111/j.1745-7254.2005.00008.x

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.

引用

页码：1 / 9

页数：9

共 83 条

[1] Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γl Fc or CH3 region [J].

Alt, M ;

Müller, R ;

Kontermann, RE .

FEBS LETTERS, 1999, 454 (1-2) :90-94

[2] A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors [J].

Arndt, MAE ;

Krauss, J ;

Kipriyanov, SM ;

Pfreundschuh, M ;

Little, M .

BLOOD, 1999, 94 (08) :2562-2568

[3] Antiangiogenic tumour therapy: will it work? [J].

Augustin, HG .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (06) :216-222

[4] Therapeutic antibody gene transfer: An active approach to passive immunity [J].

Bakker, JM ;

Bleeker, WK ;

Parren, PWHI .

MOLECULAR THERAPY, 2004, 10 (03) :411-416

[5] Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells [J].

Blanco, B ;

Holliger, P ;

Vile, RG ;

Alvarez-Vallina, L .

JOURNAL OF IMMUNOLOGY, 2003, 171 (02) :1070-1077

[6] CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation [J].

Brandao, JG ;

Scheper, RJ ;

Lougheed, SM ;

Curiel, DT ;

Tillman, BW ;

Gerritsen, WR ;

van den Eertwegh, AJM ;

Pinedo, HM ;

Haisma, HJ ;

de Gruijl, TD .

VACCINE, 2003, 21 (19-20) :2268-2272

[7] A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [J].

Bruenke, J ;

Fischer, B ;

Barbin, K ;

Schreiter, K ;

Wachter, Y ;

Mahr, K ;

Titgemeyer, F ;

Niederweis, M ;

Peipp, M ;

Zunino, SJ ;

Repp, R ;

Valerius, T ;

Fey, GH .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :167-179

[8] Production of human antibody repertoires in transgenic mice [J].

Bruggemann, M ;

Taussig, MJ .

CURRENT OPINION IN BIOTECHNOLOGY, 1997, 8 (04) :455-458

[9]

Brüsselbach S, 1999, TUMOR TARGET, V4, P115

[10] Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells [J].

Cochlovius, B ;

Kipriyanov, SM ;

Stassar, MJJG ;

Christ, O ;

Schuhmacher, J ;

Strauss, G ;

Moldenhauer, G ;

Little, M .

JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :888-895

← 1 2 3 4 5 6 7 8 9 →